How AI is Transforming Healthcare and Saving Lives | News Direct

How AI is Transforming Healthcare and Saving Lives

News release by MarketJar

facebook icon linkedin icon twitter icon pinterest icon email icon Vancouver, BC | February 21, 2024 08:30 AM Eastern Standard Time

 

Artificial intelligence (AI) is completely transforming everyday life.

From entertainment to transportation, AI is being used to make our lives easier and more efficient. But none of those applications compare to its life-altering impact on healthcare.

AI is an absolute game-changer for the healthcare industry, helping save countless lives through precision medicine, robotics-assisted surgery, and connected devices. It’s also becoming increasingly valuable in identifying complex illnesses at an earlier stage.

AI-powered diagnostics leverage machine learning algorithms to analyze diverse data like medical records, genetics, and scans for early disease detection by identifying subtle patterns and anomalies often missed by human doctors.

AI's rapid and precise data processing highlights subtle health changes, potentially revealing underlying diseases or risk factors. For instance, AI can review mammograms to detect early-stage breast cancer not visible to the naked eye.

Over the next five years, the AI healthcare market is expected to grow at a compound annual growth rate (CAGR) of 48.1%, jumping from $20.9 billion in 2024 to $148.4 billion by 2029.

As Big Pharma companies roll out bold AI plans for the coming years, one company is developing and acquiring technology and clinical expertise to create an AI-driven medical powerhouse that supports doctors, curbs rising healthcare costs and improves patient outcomes.

 HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF is a physician-led healthcare technology company that is focused on AI and data science for preventive care.

In a whirlwind four months since its debut on the Toronto Stock Exchange, HEALWELL AI has rapidly gained financial strength, securing approximately $29.5 million and firmly establishing itself as a savvy capital allocator in the AI healthcare space after completing two transformative acquisitions.

AI Accelerated Preventive Healthcare

Late last year, HEALWELL AI secured a majority stake in Pentavere, a globally recognized, award-winning AI healthcare company specializing in identifying eligible patients for approved treatments. With a successful history of real-world evidence studies and key hospital network collaborations, Pentavere's DARWEN™ AI technology carries validation from global pharmaceutical leaders and has garnered recognition in renowned publications worldwide.

The Pentavere deal will provide several key benefits including significant top-line revenue growth through Pentavere's established client base and successful commercialization of real-world evidence studies, strong partnerships with major hospital networks in Canada and the US to expand HEALWELL's market reach and grant access to new patient demographics, and a team of AI engineers with invaluable to fortify the company's technological capabilities.

Following the completion of the acquisition, Pentavere introduced DERMAID, an innovative Real-World Evidence (RWE) solution tailored for Dermatologists and life sciences firms. Leveraging the DARWEN™ AI platform, DERMAID extracts actionable clinical insights to enhance patient care decisions in dermatology. The product has quickly gained traction in the market and has already engaged in commercial activities with multiple leading pharmaceutical companies.

 HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF also just finalized the acquisition of Intrahealth Systems, a multinational SaaS-based EHR (Electronic Health Record) provider supporting 15,000 clinicians that care for millions of patients in its global network across Canada, Australia and New Zealand.

In 2024, Intrahealth is projected to generate over $12 million in revenue, showing double-digit organic growth. Historically, the company has maintained strong financial performance with over 80% gross margins, positive EBITDA, and positive cash flow. Moreover, more than 80% of its revenue comes from recurring sources, which are highly profitable.

HEALWELL's strategic vision involves a deep integration of its cutting-edge AI tools with Intrahealth's platform to pioneer a next-generation AI-powered EHR, aligning with Value-Based Care (VBC) trends and empowering healthcare providers to achieve better health outcomes at reduced costs.

HEALWELL has solidified its support structure through a strategic partnership with WELL Health Technologies, the largest clinic group in Canada. WELL Health has invested in each of HEALWELL's financings, making them the largest shareholder and helping position HEALWELL as a leader in AI-enabled healthcare technology in North America.

The alliance between WELL Health and HEALWELL led to the launch of the WELL AI Decision Support service for healthcare providers. This new service is designed to be highly adaptable and is expected to grow over time. Initially, WELL AI Decision Support will enable healthcare providers to accurately identify over 150 complex or rare diseases that are often overlooked by traditional methods.

HEALWELL AI is actively pursuing a robust pipeline of potential acquisitions, having evaluated over 100 opportunities to date. Heading into 2024, the company is in talks with various parties to identify new investment and acquisition targets. Their M&A approach focuses on companies with solid revenue, positive EBITDA, and promising growth prospects.

Click on this link or check out the investor presentation to learn more about HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF).

 

Disclosure:

 

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies outlined in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

 

2) The Article was issued on behalf of Healwell AI Inc. Market Jar Media Inc. was not paid for the production and publishing of this article by Healwell AI Inc.

 

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

 

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com.

 

5) An officer of Market Jar Media Inc. holds 5,483 shares that were purchased at a price of C$0.80 per share on December 20th, 2023.

 

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Healwell AI Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Healwell AI Inc.’s industry; (b) market opportunity; (c) Healwell AI Inc.’s business plans and strategies; (d) services that Healwell AI Inc. intends to offer; (e) Healwell AI Inc.’s milestone projections and targets; (f) Healwell AI Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Healwell AI Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Healwell AI Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Healwell AI Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Healwell AI Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) the accuracy of budgeted costs and expenditures; (e) Healwell AI Inc.’s ability to attract and retain skilled personnel; (f) political and regulatory stability; (g) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (h) changes in applicable legislation; (i) stability in financial and capital markets; and (j) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Healwell AI Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Healwell AI Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Healwell AI Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Healwell AI Inc.’s business operations (e) Healwell AI Inc. may be unable to implement its growth strategy; and (f) increased competition.Except as required by law, Healwell AI Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Healwell AI Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Healwell AI Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

 

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Healwell AI Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Healwell AI Inc. or such entities and are not necessarily indicative of future performance of Healwell AI Inc. or such entities.

 

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

 

Contact Details

 

James Young

 

+1 800-340-9767

 

campaigns@pressreach.com

 

Company Website

 

https://pressreach.com